Inflammatory and endothelial dysfunction markers in females with metabolic syndrome aged 50–75 years
暂无分享,去创建一个
[1] A. Kuryłowicz. Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction , 2023, Biomedicines.
[2] Jie Liu,et al. Burden of Metabolic Syndrome Among a Low-Income Population in China: A Population-Based Cross-Sectional Study , 2022, Diabetes, metabolic syndrome and obesity : targets and therapy.
[3] D. M. Tran,et al. A Cross-Sectional Study of Serum Ferritin Levels in Vietnamese Adults with Metabolic Syndrome , 2022, Diabetes, metabolic syndrome and obesity : targets and therapy.
[4] Safeera Khan,et al. The Effect of Statin Therapy on Inflammatory Biomarkers: A Systematic Review , 2021, Cureus.
[5] F. Azizi,et al. Dietary and lifestyle inflammatory scores are associated with increased risk of metabolic syndrome in Iranian adults , 2021, Diabetology & Metabolic Syndrome.
[6] N. Agarwal,et al. Association of Serum Ferritin Levels with Metabolic Syndrome in India: a Cross-Sectional Study. , 2021, Maedica.
[7] B. Elmas,et al. Pentraxin 3 as a Marker for Cardiovascular Disease Risk in Overweight and Obese Children. , 2021, Acta Cardiologica Sinica.
[8] G. Yuan,et al. Combined Associations of Serum Ferritin and Body Size Phenotypes With Cardiovascular Risk Profiles: A Chinese Population-Based Study , 2021, Frontiers in Public Health.
[9] C. Rubira,et al. Association of Metabolic Syndrome and Hyperferritinemia in Patients at Cardiovascular Risk , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.
[10] H. Falhammar,et al. Genetic and Biological Effects of ICAM-1 E469K Polymorphism in Diabetic Kidney Disease , 2020, Journal of diabetes research.
[11] H. Lee,et al. The association between metabolic components and markers of inflammatory and endothelial dysfunction in adolescents, based on the Ewha Birth and Growth Cohort Study , 2020, PloS one.
[12] Juan Antonio López-Rivera,et al. The Impact of Education and Age on Metabolic Disorders , 2020, Frontiers in Public Health.
[13] X. Shao,et al. High-Sensitivity C-Reactive Protein Leads to Increased Incident Metabolic Syndrome in Women but Not in Men: A Five-Year Follow-Up Study in a Chinese Population , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.
[14] Sujata Sharma,et al. A Prospective Study on the Incidence of Metabolic Syndrome in Premenopausal and Postmenopausal Women , 2020, Journal of mid-life health.
[15] P. Kris-Etherton,et al. Aging women and their endothelium: Probing the relative role of estrogen on vasodilator function. , 2019, American journal of physiology. Heart and circulatory physiology.
[16] M. Shin,et al. Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study , 2019, Journal of atherosclerosis and thrombosis.
[17] D. R. Rios,et al. Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation , 2019, International journal of molecular sciences.
[18] A. Gabrielsen,et al. hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare‐Based Study , 2019, Journal of the American Heart Association.
[19] Y. Takashi,et al. Circulating pentraxin 3 is positively associated with chronic hyperglycemia but negatively associated with plasma aldosterone concentration , 2018, PloS one.
[20] R. Jayawardena,et al. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review , 2017, BMC Public Health.
[21] P. Altieri,et al. The Metabolic Syndrome in Hispanics – The Role of Inflammation , 2015 .
[22] Feng Liu,et al. Pentraxin 3 as a Prognostic Biomarker in Patients with Systemic Inflammation or Infection , 2014, Mediators of inflammation.
[23] S. Motor,et al. Serum Pentraxin-3 Levels Are Associated with the Severity of Metabolic Syndrome , 2012, Medical Principles and Practice.
[24] T. Kodama,et al. Reciprocal Contribution of Pentraxin 3 and C‐Reactive Protein to Obesity and Metabolic Syndrome , 2010, Obesity.
[25] A. Karaman,et al. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. , 2009, Metabolic syndrome and related disorders.
[26] G. Biolo,et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile , 2009, Clinical and Experimental Medicine.
[27] R. Krauss,et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.
[28] L. Almasy,et al. Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans. , 2004, Diabetes.
[29] A. Ayaz,et al. Adipokines, inflammation, oxidative stress: critical components in obese women with metabolic syndrome , 2021 .
[30] S. Kurtoğlu,et al. Plasma Pentraxin 3 as a Biomarker of Metabolic Syndrome , 2014, The Indian Journal of Pediatrics.
[31] M. Uzunlulu,et al. Pentraxin 3 Levels as a Marker of Chronic Inflammation in Patients With Metabolic Syndrome , 2012 .
[32] T. Kodama,et al. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations , 2009, Clinical chemistry and laboratory medicine.
[33] A. Sañudo,et al. Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.